|
|
|
|
|
What to Expect from the Upcoming 2024 European Society of Medical Oncology Annual Meeting |
|
|
|
| Bayer to Present New Prostate Cancer Data and Continued Oncology Portfolio Research at ESMO 2024 |
| PRESS RELEASE |
| At ESMO 2024, Bayer will present key results from the Phase III ARANOTE trial on NUBEQA® (darolutamide) for metastatic hormone-sensitive prostate cancer and the PEACE-III study of XOFIGO® (radium-223) combined with enzalutamide for metastatic castration-resistant prostate cancer. The company will also share new data on VITRAKVI® (larotrectinib) in TRK fusion cancer and early-stage research for BAY 2927088 in HER2-mutated non-small cell lung cancer. |
|
|
|
|
|
| Lantheus to Present Additional Clinical Data from Phase 3 Pivotal SPLASH Trial in PSMA-Positive Metastatic Castration-Resistant Prostate Cancer During ESMO Congress 2024 |
| PRESS RELEASE |
| At ESMO 2024, Lantheus will present additional clinical data from the Phase 3 SPLASH trial on 177Lu-PNT2002, a PSMA-targeted radioligand therapy for metastatic castration-resistant prostate cancer (mCRPC). Oliver Sartor, MD, from the Mayo Clinic, will discuss the efficacy of 177Lu-PNT2002 following progression on androgen-receptor pathway inhibitors (ARPI). This therapy, which has received FDA Fast Track designation, offers potential for improving outcomes in PSMA-positive mCRPC patients. |
|
|
|
|
|
|
Friday, September 13, 2024
|
|
| Proffered Paper Session 1: GU Tumours, Non-Prostate |
|
|
|
|
LBA73 - Tivozanib–Nivolumab vs Tivozanib Monotherapy in Patients with Renal Cell Carcinoma (RCC) Following 1 or 2 Prior Therapies including an Immune Checkpoint Inhibitor (ICI) – Results of the Phase III TiNivo-2 Studya full dose?
Presented By: Toni K. Choueiri, MD
|
|
|
|
|
LBA74 - Final Analysis of the Phase 3 LITESPARK-005 Study of Belzutifan Versus Everolimus in Participants (Pts) with Previously Treated Advanced Clear Cell Renal Cell Carcinoma (ccRCC)
Presented By: Brian I. Rini, MD
|
|
|
|
|
LBA75 - Prospective Randomised Phase-II Trial of Ipilimumab/Nivolumab Versus Standard of Care in Non-Clear Cell Renal Cell Cancer - Results of the SUNNIFORECAST Trial
Presented By: Lothar Bergmann, MD
|
|
|
|
|
|
Saturday, September 14, 2024
|
|
| Presidential Symposium I: Practice-Changing Trials |
|
|
|
|
Radium-223 (Ra223) and Enzalutamide in Asymptomatic or Mildly Symptomatic Patients with Bone Metastatic Castration-Resistant Prostate Cancer (mCRPC): First Results of EORTC-GUCG 1333/PEACE-3
Presented By: Silke Gillessen, MD
|
|
|
|
|
| Addressing Uncertainties in the Management of Urothelial and Renal Cell Carcinomas
|
|
|
|
|
| What’s on the Horizon for Metastatic Prostate Cancer Patients? |
|
|
|
|
| Biochemical Failure Post-Local Therapy: An Opportunity for Tailored Treatment? |
|
|
|
|
|
Sunday, September 15, 2024
|
|
| Mini Oral Session: GU Tumours, Non-Prostate
|
|
|
|
|
LBA85 - TAR-200 +/- Cetrelimab (CET) and CET Alone in Patients (Pts) with Bacillus Calmette-Guérin-Unresponsive (BCG UR) High-Risk Non–muscle-Invasive Bladder Cancer (HR NMIBC): Updated Results from SunRISe-1 (SR-1)
Presented By: Michiel S. Van der Heijden, MD, PhD
1964MO - Alliance A031501: AMBASSADOR Study of Adjuvant Pembrolizumab (Pembro) in Muscle-Invasive Urothelial Carcinoma (MIUC) vs Observation (Obs): Extended Follow-up Disease-Free Survival (DFS) Results and Metastatic (Met) Disease Recurrence Distribution
Presented By: Andrea B. Apolo, MD
|
|
|
|
|
|
|
|
LBA76 - Anlotinib in Combined with Anti-PD-L1 Antibody Benmelstobart(TQB2450) Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma (RCC) -a Randomized, Open-Label, Phase III Study (ETER100)
Presented By: Xinan Sheng, PhD
|
|
|
|
|
LBA77 - Fecal Microbiota Transplantation (FMT) Versus Placebo in Patients Receiving Pembrolizumab plus Axitinib for Metastatic Renal Cell Carcinoma. Preliminary Results of the Randomized Phase 2 TACITO Trial.
Presented By: Chiara Ciccarese, MD
|
|
|
|
|
| Proffered paper session: GU Tumours, Prostate |
|
|
|
|
LBA65 - Efficacy of 177Lu-PNT2002 in PSMA-Positive mCRPC Following Progression on an Androgen-Receptor Pathway Inhibitor (ARPI) (SPLASH)
Presented By: Oliver Sartor, MD
|
|
|
|
|
LBA66 - UpFrontPSMA : A Randomised Phase 2 Study of Sequential 177Lu-PSMA-617 and Docetaxel (D) Versus Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Presented By: Arun A. Azad, MBBS, PhD, FRACP
|
|
|
|
|
LBA67 - Cabozantinib (C) Plus Atezolizumab (A) Versus 2nd Novel Hormonal Therapy (NHT) in Patients (Pts) with Metastatic Castration-Resistant Prostate Cancer (mCRPC): Final Overall Survival (OS) Results of the Phase 3, Randomized, CONTACT-02 Study
Presented By: Neeraj Agarwal, FASCO, MD
|
|
|
|
|
1596O - Decipher mRNA Score for Prediction of Survival Benefit from Docetaxel at Start of Androgen Deprivation Therapy (ADT) for Advanced Prostate Cancer (PC): An Ancillary Study of the STAMPEDE Docetaxel Trials
Presented By: Emily Grist, BSc, MBBS, MRCP
|
|
|
|
|
| Presidential Symposium II: Practice-Changing Trials |
|
|
|
|
LBA5 - a Randomized Phase 3 Trial of Neoadjuvant Durvalumab plus Chemotherapy Followed by Radical Cystectomy and Adjuvant Durvalumab in Muscle-Invasive Bladder Cancer (NIAGARA)
Presented By: Thomas Powles, MBBS, MRCP, MD
|
|
|
|
|
|
Monday, September 16, 2024
|
|
| Proffered Paper Session 2: GU, Non-Prostate |
|
|
|
|
LBA84 - TAR-200 plus Cetrelimab (CET) or CET Alone as Neoadjuvant Therapy in Patients (Pts) with Muscle-Invasive Bladder Cancer (MIBC) Who Are Ineligible for or Refuse Neoadjuvant Cisplatin-Based Chemotherapy (NAC): Interim Analysis of SunRISe-4 (SR-4)
Presented By: Andrea Necchi, MD
|
|
|
|
|
1962O - Health-Related Quality of Life from the CheckMate 901 Trial of Nivolumab as First-Line Therapy for Unresectable or Metastatic Urothelial Carcinoma
Presented By: Jens Bedke, MD
|
|
|
|
|
| Mini Oral Session: GU Tumours, Prostate
|
|
|
|
|
LBA68 - Efficacy and Safety of Darolutamide plus Androgen-Deprivation Therapy (ADT) in Patients with Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) from the Phase 3 ARANOTE Trial
Presented By: Fred Saad, MD, FRCS
LBA69 - Prostate Cancer Efficacy Results from a Randomised Phase 3 Evaluation of Transdermal Oestradiol (tE2) Versus Luteinising Hormone Releasing Hormone Agonists (LHRHa) for Androgen Suppression in Non-Metastatic (M0) Prostate Cancer
Presented By: Ruth Langley, MDNon-Metastatic (M0)
Invited Discussant 1595MO, LBA68 and LBA69
Presented By: Niven Mehra, MD, PhD
|
|
|
|
|
|
|
|
LBA70 - Adding Metformin to Androgen Deprivation Therapy (ADT) for Patients (Pts) with Metastatic Hormone Sensitive Prostate Cancer (mHSPC): Overall Survival (OS) Results from the Multi-Arm, Multi-Stage Randomised Platform Trial STAMPEDE
Presented By: Silke Gillessen, MD
|
|
|
|
|
LBA71 - Open-Label, Multicentre Randomised Trial of Radium223-Docetaxel Versus Docetaxel-Radium223 Sequence in Metastatic Castration Resistant Prostate Cancer (mCRPC) with Prospective Biomarker Evaluation (RAPSON Study)
Presented By: Vincenza Conteduca, MD, PhD
|
|
|
|
|
LBA72 - Nivolumab 3mg/kg and Ipilimumab 1mg/kg (Nivo3/ipi1) in Molecularly Selected Patients (Pts) with Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Presented By: Niven Mehra, MD, PhD
|
|
|
|
|
|
|
1599P - Symptomatic Skeletal Events, Health-Related Quality of Life and Pain in a Phase 3 Study of [177Lu]Lu-PSMA-617 in Taxane-Naive Patients with PSMA-Positive Metastatic Castration-Resistant Prostate Cancer: Third Interim Analysis of PSMAfore
Presented By: Karim Fizazi, MD, PhD
|
|
|
|
|
1601P - First Results from ZZFIRST: A Randomized Phase II Trial of Enzalutamide (EZ) with or Without Talazoparib (TALA) in Metastatic Hormone-Naïve Prostate Cancer (mHNPC)
Presented By: Joaquin Mateo, MD, PhD
|
|
|
|
|
1604P - PSMA-Targeted Radioligand Therapy (RLT) with 131I-LNTH-1095 (1095) plus Enzalutamide (Enza) vs Enza Alone in Chemotherapy-Naïve Patients (Pts) Whose Piflufolastat F 18-Avid Metastatic Castration-Resistant Prostate Cancer (mCRPC) Progressed on Abiraterone (Abi): ARROW
Presented By: Evan Yu , MD
|
|
|
|
|
1629P - Lutetium-177–Prostate-Specific Membrane Antigen (177Lu-PSMA) Therapy in Patients (Pts) with Prior Radium‑223 (223Ra)
Presented By: Kambiz Rahbar, MD, PhD
|
|
|
|
|
1657TiP - The STAMPEDE2 Stereotactic Ablative Body Radiotherapy (SABR) Trial: A Phase III, Randomised, Open-Label Trial in Patients with Newly Diagnosed Oligometastatic Prostate Cancer (PC) Starting Androgen Deprivation Therapy (ADT)
Presented By: Hoda Abdel-Aty , MD
|
|
|
|
|
1968P - Study EV-103 Dose Escalation/Cohort A (DE/A): 5y Follow-Up Of First-Line (1L) Enfortumab Vedotin (EV) + Pembrolizumab (P) in Cisplatin (cis)-Ineligible Locally Advanced Or Metastatic Urothelial Carcinoma (la/mUC)
Presented By: Jonathan E. Rosenberg , MD
|
|
|
|
|
|
|
